1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.05
D/E ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.11. Benjamin Graham would praise this conservative approach, but check if excess equity dilutes returns.
0.27
Exceptionally low net debt at less than half the Drug Manufacturers - Specialty & Generic median of 2.16. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.
-104.52
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.74
Current ratio 50-75% of Drug Manufacturers - Specialty & Generic median of 2.51. Martin Whitman would look for hidden assets or working capital optimization.
51.76%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.02%. Michael Burry would check for aggressive accounting and hidden risks.
